For Physicians

Precision Oncology Starts Here: Fast, Personalized Guidance for Complex Cases

First Ascent provides real-world insights supporting oncologists in identifying the next right step in treatment planning, improving outcomes, reducing costs and mitigating side effects.

For oncologists caring for patients who have exhausted standard therapies, First Ascent provides all the data and analysis needed to help select the right combination of FDA-approved agents that best target the patient’s cancer.

We are currently involved in two clinical studies NTC05857969 & NCT06024603. Our mission is to make this platform accessible outside of a clinical trial by Q3 2024. Giving those with the rarest cancers a fighting chance. A treatment plan for every type of cancer, including all solid and all liquid tumors.

First Ascent partners with referring oncologists to identify accessible, affordable combination or mono-therapy treatment options with FDA-approved drugs. Our approach pinpoints each cancer’s vulnerabilities and broadens the scope of treatments possible for the patient.

We have done more validation studies with major cancer centers than competitors. These indicate…

  • a 13.5-fold median improvement in progression-free survival for refractory, recurrent cancers;
  • treatment plans that significantly extend life (over 80% of the time for ours vs <10% for our competition).

First Ascent partners with referring oncologists to identify accessible, affordable combination or mono-therapy treatment options with FDA-approved drugs. Our approach pinpoints each cancer’s vulnerabilities and broadens the scope of treatments possible for the patient.

We have done more validation studies with major cancer centers than competitors. These indicate…

  • a 13.5-fold median improvement in progression-free survival for refractory, recurrent cancers;
  • treatment plans that significantly extend life (over 80% of the time for ours vs <10% for our competition).

Functional Precision Medicine with Validated Clinical Impact

First Ascent Biomedical delivers AI-powered clinical decision support through a proprietary xDRIVE platform—supporting oncologists in identifying the most effective therapies for cancer patients, especially those with refractory or treatment-resistant cancers.

By testing how live cancer cells respond to up to 150+ FDA-approved therapies and combinations, xDRIVE provides patient-specific evidence on how an individual’s cancer responds in an average of 10 days. A fresh biopsy sample is all it takes to unlock the evidence-based path forward for even the most challenging cases.

Functional Ex Vivo Drug Validation

We test live tumor cells against over 150+ FDA-approved and investigational therapies to observe how they respond in real time.

Genomic Sequencing

We perform DNA and RNA sequencing to uncover underlying mutations and molecular characteristics.

AI Cancer Weakness Mapping

Our Cancer Weakness AI synthesizes functional and genomic data to reveal the patient’s specific cancer vulnerabilities.

How It Works

First Ascent Biomedical AI/ML Analysis

Collect a liquid or solid, core or needle fresh biopsy sample

First Ascent Bio Cell Enrichment

Live cancer cells are tested ex vivo against a panel of FDA-approved therapies and combinations

Physicians receive a precise report with patient-specific evidence on how the cancer responds to drugs an average of 10 days

 

Published, Proven, Patient-Centered

In a prospective clinical study published in Nature Medicine:

83% of patients received new, viable treatment options

8.5x median improvement in progression-free survival

Reports were delivered in an average of 10 days

Literature & Trials

AI/ML Individualization

Open Trials

Learn More, Refer A Patient

First Ascent can arrange a presentation on our Drug Prediction Platform and clinical results.

We are happy to work with an oncologist on a specific patient referral.

Learn More, Refer A Patient

First Ascent can arrange a presentation on our Drug Prediction Platform and clinical results.

We are happy to work with an oncologist on a specific patient referral.

Learn More, Refer A Patient

First Ascent can arrange a presentation on our Drug Prediction Platform and clinical results.

We are happy to work with an oncologist on a specific patient referral.

Physician FAQs

To view the Physician FAQs, please use the button below.

Publication and Pharma Partners